Evolution of inflammation and immunity in a dengue virus 1 human infection model  

Dengue virus (DENV) infections are major causes of morbidity and mortality throughout the tropics and subtropics. More than 400 million infections are estimated to occur every year, resulting in nearly 100 million symptomatic infections and more than 20,000 deaths. Early immune response kinetics to infection remain unclear, in large part due to the variable incubation period exhibited by the DENVs after introduction into a susceptible host. To fill this knowledge gap, we performed a comprehensive virologic and immunologic analysis of individuals experimentally infected with the underattenuated DENV-1 strain 45AZ5.

  • Adam T. Waickman

  • Joseph Q. Lu

  • HengSheng Fang

  • Mitchell J. Waldran

  • Chad Gebo

  • Jeffrey R. Currier

  • Lisa Ware

  • Liesbeth Van Wesenbeeck

  • Nathalie Verpoorten

  • Oliver Lenz

  • Lotke Tambuyzer

  • Guillermo Herrera-Taracena

  • Marnix Van Loock

  • Timothy P. Endy

  • Stephen J. Thomas

    Increasingly expanded future risk of dengue fever in the Pearl River Delta, China  

In recent years, frequent outbreaks of dengue fever (DF) have become an increasingly serious public health issue in China, especially in the Pearl River Delta (PRD) with fast socioeconomic developments. Previous studies mainly focused on the historic DF epidemics, their influencing factors, and the prediction of DF risks. However, the future risks of this disease under both different socioeconomic development and representative concentration pathways (RCPs) scenarios remain little understood.

    A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge Strain  

Dengue human infection models (DHIM) have been used as a safe means to test the viability of prophylaxis and therapeutics.

    Potential effects of climate change on dengue transmission dynamics in Korea  

Dengue fever is a major international public health concern, with more than 55% of the world population at risk of infection. Recent climate changes related to global warming have increased the potential risk of domestic outbreaks of dengue in Korea. In this study, we develop a two-strain dengue model associated with climate-dependent parameters based on Representative Concentration Pathway (RCP) scenarios provided by the Korea Meteorological Administration.

    Dengue: Nucleocytoplasmic Trafficking of Dengue Non-structural Protein 5 as a Target for Antivirals  

Signal-dependent movement of proteins into and out of the nucleus through the importin superfamily of transporters is central to the replication of many viruses in infected cells, including RNA viruses such as the flavivirus Dengue virus (DENV).

  • David A. Jans
  • Alexander J. Martin
    Zika: Nuclear import inhibitor N-(4-hydroxyphenyl) retinamide targets Zika virus (ZIKV) nonstructural protein 5 to inhibit ZIKV infection  

In the absence of approved therapeutics, Zika virus (ZIKV)'s recent prolific outbreaks in the Americas, together with impacts on unborn fetuses of infected mothers, make it a pressing human health concern worldwide. Although a key player in viral replication in the infected host cell cytoplasm, ZIKV non-structural protein 5 (NS5) appears to contribute integrally to pathogenesis by localising in the host cell nucleus, in a similar fashion to NS5 from Dengue virus (DENV).

  • Chunxiao Wang
  • Sundy N Y Yang
  • Kate Smith
  • Jade K Forwood
  • David A Jans
    Zika: Antiviral activity of N-(4-hydroxyphenyl) retinamide (4-HPR) against Zika virus  

The rapid spread of Zika virus (ZIKV) in recent years has highlighted the severe diseases associated with ZIKV infection, such as Guillain-Barré syndrome in adults and microcephaly in newborns; yet no vaccines or antivirals currently exist to prevent or treat ZIKV infection.

  • Jared D Pitts
  • Pi-Chun Li
  • Melissanne de Wispelaere
  • Priscilla L Yang
    Dengue: The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication  

Dengue virus (DENV), a member of the Flaviviridae family, is a mosquito-borne pathogen and the cause of dengue fever. The increasing prevalence of DENV worldwide heightens the need for an effective vaccine and specific antivirals. 

    Dengue: A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection  

Dengue virus (DENV) is estimated to cause 390 million infections each year, but there is no licensed vaccine or therapeutic currently available.